Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20154334 | 1.00 | ALDH1A1 (0.61) | ALDH1A1FFAR1FFAR4MEN1KMT2A | |
| SCHEMBL2410348 | 0.86 | ALDH1A1 (0.81) | ALDH1A1FFAR1FFAR4MEN1KMT2A | |
| SCHEMBL168214 | 0.86 | ALDH1A1 (0.81) | ALDH1A1FFAR1FFAR4MEN1KMT2A | |
| SCHEMBL5394356 | 0.86 | ALDH1A1 (0.81) | ALDH1A1FFAR1FFAR4MEN1KMT2A | |
| SCHEMBL8564464 | 0.86 | ALDH1A1 (0.81) | ALDH1A1FFAR1FFAR4MEN1KMT2A | |
| SCHEMBL13714936 | 0.86 | ALDH1A1 (0.81) | ALDH1A1FFAR1FFAR4MEN1KMT2A | |
| SCHEMBL168532 | 0.86 | ALDH1A1 (0.81) | ALDH1A1FFAR1FFAR4MEN1KMT2A | |
| SCHEMBL2484949 | 0.86 | ALDH1A1 (0.81) | ALDH1A1FFAR1FFAR4MEN1KMT2A | |
| SCHEMBL22406917 | 0.86 | ALDH1A1 (0.81) | ALDH1A1FFAR1FFAR4MEN1KMT2A | |
| SCHEMBL17061008 | 0.86 | ALDH1A1 (0.81) | ALDH1A1FFAR1FFAR4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908999-B2 | Hydrolysis of N,N-disubstituted (2-(4-(alpha-phenyl-p-chloro-benzyl)piperazin-1-yl)ethoxy)acetamide, to form cetirizine and salts, used as antiallergens | EGIS GYOGYSZERGYAR RT. (HU) | 2005-06-21 | — | — | US | disclosed |
| EP-1233954-B1 | A PROCESS FOR THE PREPARATION OF 2- 4-(ALPHA-PHENYL-P-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2004-10-20 | — | — | EP | disclosed |
| US-20030092911-A1 | Hydrolysis in presence of phase transfer agents; antiallergens | EGIS GYOGYSZERGYAR RT. (HU) | 2003-05-15 | — | — | US | disclosed |
| EP-1233954-A1 | A PROCESS FOR THE PREPARATION OF 2- 4-(ALPHA-PHENYL-P-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR | EGIS GYOGYSZERGYAR RT. (HU) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001040211-A1 | A PROCESS FOR THE PREPARATION OF {2-[4-(α-PHENYL-p-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY}ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR | EGIS Gyógyszergyár Rt. (HU) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092911-A1 | Hydrolysis in presence of phase transfer agents; antiallergens | CMA1, NAT1, CPN1 | ALDH1A1 538/4885FFAR1 1566/4885FFAR4 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.